Company intelligence / Profile preview

Pulsar Vascular

San Jose / Los Gatos, California, United Statesjnj.com ↗

Ownership: Private
Development stage: Other

Overview

The PulseRider device received CE Mark in late 2013 and was commercially available in nine countries. It completed a US IDE clinical trial for Humanitarian Device Exemption approval targeting wide-neck bifurcation aneurysms. The device addresses an unmet need for treating complex cerebral aneurysms with a unique saddle-shaped stent that facilitates coiling while maintaining vessel support.

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Codman Neuro was exclusive distributor pre-acquisition in EMEA regions; no major pharma partnerships disclosed beyond parent company relationship.

Beyond the preview

Go deeper on Pulsar Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulsar Vascular.

Explore the full profile